...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>PLOS Neglected Tropical Diseases >The New Anthelmintic Tribendimidine is an L-type (Levamisole and Pyrantel) Nicotinic Acetylcholine Receptor Agonist
【24h】

The New Anthelmintic Tribendimidine is an L-type (Levamisole and Pyrantel) Nicotinic Acetylcholine Receptor Agonist

机译：新的驱虫药三苯双idine是一种L型（左旋咪唑和吡喃酮）烟碱型乙酰胆碱受体激动剂。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Intestinal parasitic nematodes such as hookworms, Ascaris lumbricoides, and Trichuris trichiura are amongst most prevalent tropical parasites in the world today. Although these parasites cause a tremendous disease burden, we have very few anthelmintic drugs with which to treat them. In the past three decades only one new anthelmintic, tribendimidine, has been developed and taken into human clinical trials. Studies show that tribendimidine is safe and has good clinical activity against Ascaris and hookworms. However, little is known about its mechanism of action and potential resistance pathway(s). Such information is important for preventing, detecting, and managing resistance, for safety considerations, and for knowing how to combine tribendimidine with other anthelmintics.
机译：背景技术诸如钩虫，A虫和Trichuris trichiura的肠道寄生线虫是当今世界上最流行的热带寄生虫。尽管这些寄生虫会造成巨大的疾病负担，但我们几乎没有用于治疗它们的驱虫药。在过去的三十年中，仅开发了一种新的驱虫药曲本苯二胺，并将其用于人体临床试验。研究表明三苯二im是安全的，并且对against虫和钩虫具有良好的临床活性。但是，对其作用机理和潜在的抗药性途径知之甚少。此类信息对于预防，检测和管理耐药性，出于安全考虑以及了解如何将曲苯二idine与其他驱虫药结合使用非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号